
The HALO ablation technology is designed to remove the Barrett's epithelium in a short, well-tolerated endoscopic procedure and offers an alternative to "watchful waiting" for patents with intestinal metaplasia, low-grade dysplasia, and high-grade dysplasia. The HALO technology consists of two different devices and accessories. The balloon-based HALO360+ device is capable of treating larger areas of circumferential Barrett's esophagus, while the HALO90 focal ablation device is used to treat smaller areas. The HALO accessories include the HALO Guidewire and HALO CAP, which are specifically designed to facilitate the ablation procedure. Advanced HALO Ablation Technology, Clinically Tested
- Tightly controlled, uniformed ablation of the epithelium
- Clinical evaluations completed for all types of Barrett's tissue: intestinal metaplasia, low-grade dysplasia, and high-grade dysplasia
- Retreatment is possible, as necessary
- Leading-edge-technology results in fast, straightforward, uniform treatment
Halo Technology
The proprietary technology incorporated in the HALO360 and HALO90 Systems is designed to maximize clinical outcomes and completely remove the Barrett's epithelium without significant injury to the underlying tissue.
Delivery of ablative energy in less than 1 second allows long or short segments of Barrett's to be treated quickly Consistent application of bipolar energy uniformly removes the esophageal epithelium, reducing potential for buried glands and improving patient tolerability Controlled treatment depth of less than 1,000 µm reduces risk of stricture formation, even after multiple energy applications

Bipolar electrode array geometry precisely controls the depth of ablation to < 1 mm.
Precise Depth Control
Barrett's epithelium is approximately 500 µm in thickness. The HALO Energy Generator and the HALO Ablation Catheter electrode array are designed to work in concert to achieve a uniform, superficial depth of ablation of ~1,000 µm.

Human Esophagus Specimen (H&E Stain)
Predictable Outcome
In both porcine and human esophagectomy studies, the HALO Technology has demonstrated removal of the esophageal epithelium without significant injury to the submucosa when using the recommended treatment settings
 |  | | Non-ablated esophagus Epithelium intact | 48 hours Post-Ablation Absence of epithelium with preservation of lamina propria and muscularis mucosae. |
|
Category: Interventional > Barrx Medical - Halo Products |
|